Clinical Trial Update: Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease [Phase 2]

View source ↗

Summary

Phase 2 safety study of CTA018 injection for Stage 5 chronic kidney disease has completed. The trial targeted patients with secondary hyperparathyroidism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism
• Renal Failure
• Renal Insufficiency

Drugs mentioned

• CTA018

Snippet

Sponsor: OPKO IP Holdings II, Inc. | Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED